Flash Glucose Monitoring Accepted in Daily Life of Children and Adolescents with Type 1 Diabetes and Reduction of Severe Hypoglycemia in Real-Life Use
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Flash glucose monitoring (FGM) is covered by the Belgian public health insurance for type 1 diabetes since 2016. The objective of this study was to describe the use of FGM and diabetes outcomes in type 1 diabetic children and adolescents 1 year after reimbursement. Methods: All patients had the choice to convert to FGM or to continue with self-monitoring of blood glucose (SMBG). Clinical data were collected at baseline, at the next visit, and after 12 months; glucose profiles at next visit and after 12 months. Regression analyses were performed to identify predictors of FGM acceptance and changes in metabolic control. Results: A total of 334 subjects were included, of whom 278 (83.2%) switched to FGM. They were younger (13.6 vs. 15.2 years; P = 0.012) and performed more SMBG testing at baseline than patients who did not switch (4.3 vs. 4.1 tests daily; P = 0.008). At the end of follow-up, the rate of severe hypoglycemia decreased by 53% in the group of FGM users ( P = 0.012) while it remained stable in SMBG users. Median glycated hemoglobin did not change significantly in both groups. Among subjects who switched to FGM, 15.8% reverted to SMBG after a median use of 5.3 months. Adverse events, diabetes duration, and FGM utilization were independent predictors of the risk for reverting. FGM-related adverse events were associated with a fivefold increased risk to revert to SMBG (hazard ratio = 5.12; P < 0.0001). Conclusions: FGM is relatively well accepted and decreases the risk of severe hypoglycemic events in our pediatric population. FGM is more often discontinued in patients experiencing adverse events and with longer diabetes duration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
A Tale of Two Compartments: Interstitial Versus Blood Glucose Monitoring
Cengiz, E., & Tamborlane, W. V. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0002 · Cited by 390 · cited 1×
“16 Thus, a feeling of poor reliability could have played a role in the decision to stop the FGM, especially in case of diabetes with higher variability.”
Weight Gain Associated With Intensive Therapy in the Diabetes Control and Complications Trial
The DCCT Research Group (1988) · Diabetes Care · doi:10.2337/diacare.11.7.567 · Cited by 345
Ziegler, R., Heidtmann, B., Hilgard, D., Hofer, S., Rosenbauer, J., Holl, R., & DPV-Wiss-Initiative, F. T. (2011) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2010.00650.x · Cited by 334 · cited 1×
“We hypothesize that the decreased occurrence of SH in our study is mainly related to the increased frequency of glucose controls allowed by the FGM as we know that the hypoglycemia risk may be affected by glucose monitoring frequency.(22) Unexpectedly, we did not observe an HbA1c reduction in the group of the FGM user…”
Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry
Wong, J. C., Foster, N. C., Maahs, D. M., Raghinaru, D., Bergenstal, R. M., Ahmann, A. J., Peters, A. L., Bode, B. W., Aleppo, G., Hirsch, I. B., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0303 · Cited by 318
Reddy, M., Jugnee, N., El Laboudi, A., Spanudakis, E., Anantharaja, S., & Oliver, N. (2018) · Diabetic Medicine · doi:10.1111/dme.13561 · Cited by 245 · cited 1×
“A recent study comparing FGM and CGM showed that FGM is relatively inefficient to decrease hypoglycemia in type 1 diabetic adults with impaired awareness of hypoglycemia (IAH).(20) As IAH is also prevalent in pediatric populations,(21) we cannot exclude that a high prevalence of IAH in our cohort biased our findings t…”
Sartore, G., Chilelli, N. C., Burlina, S., Stefano, P. D., Piarulli, F., Fedele, D., Mosca, A., & Lapolla, A. (2012) · Acta Diabetologica · doi:10.1007/s00592-012-0391-4 · Cited by 90 · cited 1×
“Stopping FGM was also more frequent in patients with diabetes of longer duration and with higher HbA1c, the two conditions often associated with higher glucose variability.(15) We know that the accuracy of the FGM is low in hypoglycemia and during rapid change of glucose values.”
Evaluation of flash glucose monitoring after long-term use: a pediatric survey
Vergier, J., Samper, M., Dalla-Vale, F., Ventura, V., Baucher, F., Joubert, F., Pons, C., De Oliveira, M., Salet, R., Faure-Galon, N., et al. (2019) · Primary Care Diabetes · doi:10.1016/j.pcd.2018.08.004 · Cited by 32
Cited by
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Charleer, S., De Block, C., Van Huffel, L., Broos, B., Fieuws, S., Nobels, F., Mathieu, C., & Gillard, P. (2020) · Diabetes Care · doi:10.2337/dc19-1610 · Cited by 261
7. Diabetes Technology: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s007 · Cited by 202
Castellana, M., Parisi, C., Di Molfetta, S., Di Gioia, L., Natalicchio, A., Perrini, S., Cignarelli, A., Laviola, L., & Giorgino, F. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001092 · Cited by 84
Charleer, S., Gillard, P., Vandoorne, E., Cammaerts, K., Mathieu, C., & Casteels, K. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13128 · Cited by 14
Metadata
- Authors
- Messaaoui, A., Tenoutasse, S., & Crenier, L.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2019-06-01
- Volume
- 21
- Issue
- 6
- Pages
- 329-335
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2944057348
- Cited by
- 51
- References
- 8
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Flash Glucose Monitoring Accepted in Daily Life of Children and Adolescents with Type 1 Diabetes and Reduction of Severe Hypoglycemia in Real-Life Use. https://app.cochat.ai/papers/10.1089/dia.2018.0339
- The paper
- Messaaoui, A., Tenoutasse, S., & Crenier, L. (2019). Flash Glucose Monitoring Accepted in Daily Life of Children and Adolescents with Type 1 Diabetes and Reduction of Severe Hypoglycemia in Real-Life Use. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2018.0339
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.